Clinical Trials - MLTX

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT07007637A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaENROLLING_BY_INVITATIONPHASE32025-06-272028-06-132028-06-13
NCT06994936An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an AutoinjectorACTIVE_NOT_RECRUITINGPHASE12025-06-052025-10-162025-10-16
NCT06768671An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)RECRUITINGPHASE32024-12-302026-03-272026-03-27
NCT06641076Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugRECRUITINGPHASE32024-10-152027-01-152027-01-15
NCT06641089Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseRECRUITINGPHASE32024-10-152027-01-152027-01-15
NCT06411899A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaACTIVE_NOT_RECRUITINGPHASE32024-05-152026-06-172025-06-17
NCT06411379Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaACTIVE_NOT_RECRUITINGPHASE32024-05-142026-06-172025-06-17
NCT05640245Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisCOMPLETEDPHASE22022-12-132024-01-152023-09-05
NCT05322473Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaCOMPLETEDPHASE22022-04-252023-08-302023-05-09